Modulation of the natriuretic peptide system in heart failure: From bench to bedside?

Clinical Science

Volumn 105, Issue 2, 2003, Pages 141-160

  Schmitt, Matthias ^a   Cockcroft, John R ^a   Frenneaux, Michael P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Heart failure; Natriuretic peptide; Vascular resistance

Indexed keywords

A 74186; ADRENOMEDULLIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANDOXATRILAT; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENALAPRIL; FASIDOTRILAT; FOSINOPRILAT; HORMONE PRECURSOR; HS 142 1; IRBESARTAN; LISINOPRIL; MESSENGER RNA; N (1 CARBOXY 2 PHENYLETHYL)PHENYLALANYL BETA ALANINE; N(G) METHYLARGININE; NESIRITIDE; OMAPATRILAT; PHOSPHOLIPASE C; POTASSIUM CHANNEL; PROTEINASE; RECEPTOR BLOCKING AGENT; SAMAPATRILAT; UNCLASSIFIED DRUG; URODILATIN; VASOPEPTIDASE INHIBITOR;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANGIONEUROTIC EDEMA; ASTHMA; BLOOD VESSEL TONE; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR SYSTEM; CHROMOSOME 1; CHROMOSOME 2; CLINICAL RESEARCH; CLINICAL TRIAL; COW; DIURESIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME ACTIVITY; EXON; EXTRACELLULAR SPACE; GENE EXPRESSION; HEALTH CARE COST; HEART FAILURE; HEART LEFT ATRIUM PRESSURE; HUMAN; IMMUNOREACTIVITY; KIDNEY FAILURE; LUNG CAPILLARY PRESSURE; METHODOLOGY; PATHOPHYSIOLOGY; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECRETION; RABBIT; RECEPTOR BINDING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SODIUM EXCRETION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; MICE; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; PEPTIDE HORMONES;

EID: 0042591498     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20030044     Document Type: Review

References (261)

1. Maisel, A. S., Krishnaswamy, P., Nowak, R. M. et al. (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347, 161-167
2. McCullough, P. A., Nowak, R. M., McCord, J. et al. (2002) B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106, 416-422
3. Berger, R., Huelsman, M., Strecker, K. et al. (2002) B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105, 2392-2397
4. Troughton, R. W., Frampton, C., Yandle, T., Espiner, E. A., Nicholls, M. G. and Richards, A. M. (2000) Treatment of heart failure guided by plasma N-terminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355, 1126-1130
5. Richards, A. M., Lainchbury, J. G., Nicholls, M. G., Troughton, R. W. and Yandle, T. (2002) BNP in hormone-guided treatment of heart failure. Trends Endocrinol. Metab. 13, 151-155
6. Henry, J. P., Gauer, O. H. and Reeves, J. L. (1956) Evidence of the atrial location of receptors influencing urine flow. Circ. Res. 4, 85-90
7. Gauer, O. H. and Henry, J. P. (1976) Neurohormonal control of plasma volume. Int. Rev. Physiol. 9, 145-190
8. Gauer, O. H., Henry, J. P. and Behn, C. (1970) The regulation of extracellular fluid volume. Annu. Rev. Physiol. 32, 547-595
9. Norsk, P. (1994) The Henry-Gauer hypothesis: is it still valid? J. Gravit. Physiol. 1, 114-117
10. Greenleaf, J. E., Shiraki, K., Sagawa, S. et al. (1999) Is the Gauer-Henry reflex important for immersion diuresis in men? Aviat. Space Environ. Med. 70, 1201-1205
11. Norsk, P. (1996) Role of arginine vasopressin in the regulation of extracellular fluid volume. Med. Sci. Sports Exercise 28, S36-S41
12. Kisch, B. (1956) Electron microscopy of the atrium of the heart. I. Guinea pig. Exp. Med. Surg. 14, 99-112
13. Wenckebach, K. F. (1906) Beitraege zur Kenntnis der menschlichen Herztaetigkeit (Contributions to the knowledge of human cardiac activity). Arch. Anat. Physiol. 297-354
14. de Bold, A. J., Borenstein, H. B., Veress, A. T. and Sonnenberg, H. (1981) A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28, 89-94
15. Flynn, T. G., de Bold, M. L. and de Bold, A. J. (1983) The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem. Biophys. Res. Commun. 117, 859-865
16. Kangawa, K. and Matsuo, H. (1984) Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide (α-hANP). Biochem. Biophys. Res. Commun. 118, 131-139
17. Atlas, S. A., Kleinert, H., Camargo, M. J. et al. (1984) Purification, sequencing, and synthesis of natriuretic and vasoactive rat atrial peptide. Nature (London) 309, 717-719
18. Oikawa, S., Imai, M., Ueno, A. et al. (1984) Cloning and sequence analysis of cDNA encoding a precursor for human atrial natriuretic polypeptide. Nature (London) 309, 724-726
19. Oikawa, S., Imai, M., Inuzuka, C. et al. (1985) Structure of clog and rabbit precursors of atrial natriuretic polypeptides deduced from nucleotide sequence of cloned cDNA. Biochem. Biophys. Res. Commun. 132, 892-899
20. Zivin, R. A., Condra, J. H., Dixon, R. A. et al. (1984) Molecular cloning and characterization of DNA sequences encoding rat and human atrial natriuretic factors. Proc. Natl. Acad. Sci. U.S.A. 81, 6325-6329
21. Greenberg, B. D., Bencen, G. H., Seilhammer, J. J., Lewicki, J. A. and Fiddes, J. C. (1984) Nucleotide sequence of the gene encoding human atrial natriuretic factor precursor. Nature (London) 312, 656-658
22. Seidman, C. E., Duby, A. D., Choi, E. et al. (1984) The structure of rat preproatrial natriuretic factor as defined by a complementary DNA clone. Science (Washington, D.C.) 225, 324-326
23. Seidman, C. E., Bloch, K. D., Klein, K. A., Smith, J. A. and Seidman, J. G. (1984) Nucleotide sequences of the human and mouse atrial natriuretic factor genes. Science (Washington, D.C.) 226, 1206-1209
24. Vesely, D. L. (1985) Atrial natriuretic hormones originating from the N-terminus of the atrial natriuretic factor prohormone. Clin. Exp. Pharmacol. Physiol. 22, 108-114
25. Schweitz, H., Vigne, P., Moinier, D., Frelin, C. and Lazdunski, M. (1992) A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J. Biol. Chem. 267, 13928-13932
26. Schirger, J. A., Heublein, D. M., Chen, H. H. et al. (1999) Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin. Proc. 74, 126-130
27. Richards, A. M., Lainchbury, J. G., Nicholls, M. G., Cameron, A. V. and Yandle, T. G. (2002) Dendroaspis natriuretic peptide: endogenous or dubious? Lancet 359, 5-6
28. Best, P. J., Burnett, J. C., Wilson, S. H., Holmes, D. R. and Lerman, A. (2002) Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc. Res. 55, 375-384
29. Chen, H. H., Lainchbury, J. G. and Burnett, J. C. (2002) Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J. Am. Coll. Cardiol. 40, 1186-1191
30. Yan, W., Wu, F., Morser, J. and Wu, Q. (2000) Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc. Natl. Acad. Sci. U.S.A. 97, 8525-8529
31. Wu, F., Yan, W., Pan, J., Morser, J. and Wu, Q. (2002) Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J. Biol. Chem. 277, 16900-16905
32. Gardner, D. G., Hedges, B. K., Wu, J., LaPointe, M. C. and Deschepper, C. F. (1989) Expression of the atrial natriuretic peptide gene in human fetal heart. J. Clin. Endocrinol. Metab. 69, 729-737
33. Johnson, D. D., Tetzke, T. A., and Cheung, C. Y. (1994) Gene expression of atrial natriuretic factor in ovine fetal heart during development. J. Soc. Gynecol. Invest. 1, 14-18
34. Larsen, T. H. (1990) Atrial natriuretic factor in the heart of the human embryo. Acta Anat. (Basel) 138, 132-136
35. Cheung, C. Y. and Roberts, V. J. (1993) Developmental changes in atrial natriuretic factor content and localization of its messenger ribonucleic acid in ovine fetal heart. Am. J. Obstet. Gynecol. 169, 1345-1351
36. Walther, T., Schultheiss, H.-P., Taschoeppe, C. and Stepan, H. (2002) Natriuretic peptide system in fetal heart and circulation. J. Hypertens. 20, 785-791
37. Delporte, C., Winand, J., Poloczek, P., Von Geldern, T. and Christophe, J. (1992) Discovery of a potent atrial natriuretic peptide antagonist for ANPA receptors in the human neuroblastoma NB-OK-1 cell line. Eur. J. Pharmacol 224, 183-188
38. Delporte, C., Poloczek, P., Tastenoy, M., Winand, J. and Christophe, J. (1992) Atrial natriuretic peptide binds to ANP-R1 receptors in neuroblastoma cells or is degraded extracellularly at the Ser-Phe bond. Eur. J. Pharmacol. 227, 247-256
39. Vesely, D. L., Douglass, M. A., Dietz, J. R. et al. (1994) Three peptides from the atrial natriuretic factor prohormone N-terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 90, 1129-1140
40. Vesely, D. L., Cornett, L. E., MacLeod, S. L., Nash, A. A. and Norris, J. S. (1990) Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126. Peptides 11, 193-197
41. + ATPase of the atrial natriuretic peptides. Endocrinology 136, 2033-2039
42. Vesely, D. L., Perez-Lamboy, G. I. and Schocken, D. D. (2000) Vessel dilator, long-acting natriuretic peptide, and kaliuretic peptide increase circulating prostaglandin E2. Life Sci. 66, 905-913
43. Edwards, B. S., Zimmerman, R. S., Schwab, T. R., Heublein, D. M. and Burnett, Jr, J. C. (1988) Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ. Res. 62, 191-195.
44. Ferrari, R. and Agnoletti, G. (1989) Atrial natriuretic peptide: its mechanism of release from the atrium. Int. J. Cardiol. 24, 137-149
45. Gardner, D. G., Newman, E. D., Nakamura, K. K. and Nguyen, K. P. (1991) Endothelin increases the synthesis and secretion of atrial natriuretic peptide in neonatal rat cardiocytes. Am. J. Physiol. 261, E177-E182
46. de Bold, A. J., Bruneau, B. G. and Kuroski de Bold, M. L. (1996) Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc. Res. 31, 7-18
47. Bruneau, B. G. and de Bold, A. J. (1994) Selective changes in natriuretic peptide and early response gene expression in isolated rat atria following stimulation by stretch or endothelin-1. Cardiovasc. Res. 28, 1519-1525
48. Ruskoaho, H., Vakkuri, O., Arjamaa, O., Vuolteenaho, O. and Leppaluoto, J. (1989) Pressor hormones regulate atrial-stretch-induced release of atrial natriuretic peptide in the pithed rat. Circ. Res. 64, 482-492
49. Schulz-Knappe, P., Forssmann, K., Herbst, F., Hock, D., Pipkorn, R. and Forssmann, W. G. (1988) Isolation and structural analysis of 'urodilatin', a new peptide of the cardiodilatin (ANP)-family, extracted from human urine. Klin. Wochenschr. 66, 752-759
50. Bub, A., Marxen, P., and Forssmann, W. G. (1993) Urodilatin (Uro) binding sites in rat kidney. Anat. Rec. 41, 14
51. Meyer, M., Richter, R., Brunkhorst, R. et al. (1996) Urodilatin is involved in sodium homeostasis and exerts sodium-state-dependent natriuretic and diuretic effects. Am. J. Physiol. 271, F489-F497
52. Forssmann, W. G., Meyer, M. and Schulz-Knappe, P. (1994) Urodilatin: from cardiac hormones to clinical trials. Exp. Nephrol. 2, 318-323
53. McKenzie, J. C., Tanaka, I., Misono, K. S. and Inagami, T. (1985) Immunocytochemical localization of atrial natriuretic factor in the kidney, adrenal medulla, pituitary, and atrium of rat. J. Histochem. Cytochem. 33, 828-832
54. Goetz, K. L. (1991) Renal natriuretic peptide (urodilatin?) and atriopeptin: evolving concepts. Am. J. Physiol. 261, F921-F932
55. Goetz, K., Drummer, C., Zhu, J. L., Leadley, R., Fiedler, F. and Gerzer, R. (1990) Evidence that urodilatin, rather than ANP, regulates renal sodium excretion. J. Am. Soc. Nephrol. 1, 867-874
56. Drummer, C., Franck, W., Heer, M., Forssmann, W. G., Gerzer, R. and Goetz, K. (1996) Postprandial natriuresis in humans: further evidence that urodilatin, not ANP, modulates sodium excretion. Am. J. Physiol. 270, F301-F310
57. Goetz, K. (1990) Evidence that atriopeptin is not a physiological regulator of sodium excretion. Hypertension 15, 9-19
58. Abassi, Z. A., Tate, J., Hunsberger, S., Klein, H., Trachewsky, D. and Keiser, H. R. (1992) Pharmacokinetics of ANF and urodilatin during cANF receptor blockade and neutral endopeptidase inhibition. Am. J. Physiol. 263, E870-E876
59. Sudoh, T., Kangawa, K., Minamino, N. and Matsuo, H. (1988) A new natriuretic peptide in porcine brain. Nature (London) 332, 78-81
60. Maekawa, K., Sudoh, T., Furusawa, M. et al. (1988) Cloning and sequence analysis of cDNA encoding a precursor for porcine brain natriuretic peptide. Biochem. Biophys. Res. Commun. 157, 410-416
61. Ogawa, Y., Nakao, K., Mukoyama, M. et al. (1991) Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ. Res. 69, 491-500
62. Bloch, K. D., Seidman, J. G., Naftilan, J. D., Fallon, J. T. and Seidman, C. E. (1986) Neonatal atria and ventricles secrete atrial natriuretic factor via tissue-specific secretory pathways. Cell (Cambridge, Mass.) 47, 695-702
63. Smith, M. W., Espiner, E. A., Yandle, T. G., Charles, C. J. and Richards, A. M. (2000) Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J. Endocrinol. 167, 239-246
64. Flynn, T. G. (1997) The biochemistry of atrial natriuretic peptides. In Natriuretic Peptides In Health And Disease (Samson, W. K. and Levin, E. R., eds.), pp. 1-20, Humana Press, Totowa, NJ
65. Bonatti, J., Dichtl, W., Lercher, A. and Puschendorf, B. (2000) Natriuretic peptides stimulate cyclic guanosine monophosphate production in human saphenous vein and internal mammary artery. Eur. J. Cardiothorac. Surg. 17, 175-181
66. Wiley, K. E. and Davenport, A. P. (2001) Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery. Br. J. Pharmacol. 133, 568-574
67. van der Zander, K., Houben, A. J., Kroon, A. A. and de Leeuw, P. W. (1999) Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide. Cardiovasc. Res. 44, 595-600
68. Nakamura, M., Arakawa, N., Yoshida, H., Makita, S., Niinuma, H. and Hiramori, K. (1998) Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am. Heart J. 135, 414-420
69. Hunt, P. J., Espiner, E. A., Nicholls, M. G., Richards, A. M. and Yandle, T. G. (1596) Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J. Clin. Endocrinol. Metab. 81, 3871-3876
70. Hunt, P. J., Espiner, E. A., Richards, A. M., Yandle, T. G., Frampton, C. and Nicholls, M. G. (1995) Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men. Am. J. Physiol. 269, R1197-R1403
71. Florkowski, C. M., Richards, A. M., Espiner, E. A., Yandle, T. G. and Frampton, C. (1994) Renal, endocrine, and hemodynamic interactions of atrial and brain natriuretic peptides in normal men. Am. J. Physiol. 266, R1244-R1250
72. Lainchbury, J. G., Richards, A. M., Nicholls, M. G. et al. (1997) The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension 30, 198-404
73. Lainchbury, J. G., Nicholls, M. G., Espiner, E. A., Yandle, T. G., Lewis, L. K. and Richards, A. M. (1999) Bioactivity and interactions of adrenomedullin and brain natriuretic peptide in patients with heart failure. Hypertension 34, 70-75
74. Pidgeon, G. B., Richards, A. M., Nicholls, M. G., Espiner, E. A., Yandle, T. G. and Frampton, C. (1996) Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension. Hypertension 27, 906-913
75. Espiner, E. A., Richards, A. M., Yandle, T. G. and Nicholls, M. G. (1995) Natriuretic hormones. Endocrinol. Metab. Clin. North Am. 24, 481-509
76. van der Zander, K., Houben, A. J., Kroon, A. A. et al. (2003) Does brain natriuretic peptide have a direct renal effect in human hypertensives? Hypertension 41, 119-123
77. Brunner-La Rocca, H. P., Woods, R. L., Kaye, D. M. et al. (2002) Divergent effects of ANP and BNP in acute heart failure: evidence for a putative BNP-selective receptor? J. Hypertens. 20, 1195-1201
78. Goy, M. F., Oliver, P. M., Purdy, K. E. et al. (2001) Evidence for a novel natriuretic peptide receptor that prefers brain natriuretic peptide over atrial natriuretic peptide. Biochem. J. 358, 379-387
79. Sudoh, T., Minamino, N., Kangawa, K. and Matsuo, H. (1990) C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem. Biophys. Res. Commun. 168, 863-870
80. Minamino, N., Kangawa, K. and Matsuo, H. (1990) N-terminally extended form of C-type natriuretic peptide (CNP-53) identified in porcine brain. Biochem. Biophys. Res. Commun. 170, 973-979
81. Imura, H., Nakao, K. and Itoh, H. (1992) The natriuretic peptide system in the brain: Implications in the central control of cardiovascular and neuroendocrine functions. Front. Neuroendocrinol. 13, 217-249
82. Lohe, A., Yeh, I., Hyver, T., Pratt, R. and Jamison, R. (1995) Natriuretic peptide B receptor and C-type natriuretic peptide in the rat kidney. J. Am. Soc. Nephrol. 6, 1552-1558
83. Kalra, P. R., Anker, S. D., Struthers, A. D. and Coats, A. J. (2001) The role of C-type natriuretic peptide in cardiovascular medicine. Eur. Heart J. 22, 997-1007
84. Stingo, A. J., Clavell, A. L., Aarhus, L. L. and Burnett, Jr, J. C. (1992) Cardiovascular and renal actions of C-type natriuretic peptide. Am. J. Physiol. 262, H308-H312
85. Honing, M. L., Smits, P., Morrison, P. J., Burnett, Jr, J. C. and Rabelink, T. J. (2001) C-type natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels. Hypertension 37, 1179-1183
86. Wei, C. M., Aarhus, L. L., Miller, V. M. and Burnett, Jr, J. C. (1993) Action of C-type natriuretic peptide in isolated canine arteries and veins. Am. J. Physiol. 264, H71-H73
87. Tolsa, J.-F, Gao, Y., Sander, F. C., Souici, A.-C., Moessinger, A. and Raj., J. U. (2002) Differential responses of newborn pulmonary arteries and veins to atrial and c-type natriuretic peptides. Am. J. Physiol. 282, H273-H280
88. Wright, R. S., Wei, C. M., Kim, C. H. et al. (1996) C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems. J. Am. Coll. Cardiol. 28, 1031-1038
89. Wei, C. M., Hu, S., Miller, V. M. and Burnett, Jr, J. C. (1994) Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 205, 765-771
90. Banks, M., Wei, C. M., Kim, C. H., Burnett, Jr, J. C. and Miller, V. M. (1996) Mechanism of relaxations to C-type natriuretic peptide in veins. Am. J. Physiol. 271, H1907-H1911
91. Webb, D. J., Benjamin, N., Allen, M. J., Brown, J., O'Flynn, M. and Cockcroft, J. R. (1988) Vascular responses to local atrial natriuretic peptide infusion in man. Br. J. Clin. Pharmacol. 26, 245-251
92. Wei, C. M., Miller, V. M., Schaff, H. V. and Burnett, Jr, J. C. (1996) Specifity of C-type ad atrial natriuretic peptides in human blood vessels. Endothelium 4, 23-28
93. Nakamura, M., Arakawa, N., Yoshida, H., Makita, S. and Hiramori, K. (1994) Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure. Circulation 90, 1210-1214
94. Ikeda, T., Itoh, H., Komatsu, Y. et al. (1996) Natriuretic peptide receptors in human artery and vein and rabbit vein graft. Hypertension 27, 833-837
95. Schmitt, M., Taylor, J., Broadley, A. et al. (2002) ANP but not CNP modulates venous capacitance in chronic heart failure. Eur. J. Heart. Failure 1, 87
96. Schmitt, M., Broadley, A., Middleton, G. et al. (2002) Preserved venous ANP responsiveness in chronic heart failure is partially mediated via endothelial nitric oxide. J. Am. Coll. Cardiol. 19, 362B
97. Kohno, M., Horio, T., Yokokawa, K., Kurihara, N. and Takeda, T. (1992) C-type natriuretic peptide inhibits thrombin- and angiotensin II-stimulated endothelin release via cyclic guanoslne 3′,5′-monophosphate. Hypertension 19, 320-325
98. Davidson, N. C., Barr, C. S. and Struthers, A. D. (1996) C-type natriuretic peptide. An endogenous inhibitor of vascular angiotensin-converting enzyme activity. Circulation 93, 1155-1159
99. Furuya, M., Yoshida, M., Hayashi, Y. et al. (1991) C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 177, 927-931
100. Furuya, M., Aisaka, K., Miyazaki, T. et al. (1993) C-type natriuretic peptide inhibits intimal thickening after vascular injury. Biochem. Biophys. Res. Commun. 193, 248-253
101. Suga, S., Nakao, K., Itoh, H. et al. (1992) Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of 'vascular natriuretic peptide system'. J. Clin. Invest. 90, 1145-1149
102. Lisy, O., Jougasaki, M., Schirger, J. A., Chen, H. H., Barclay, P. T. and Burnett, Jr, J. C. (1998) Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am. J. Physiol. 275, F410-F414
103. Charles, C. J., Espiner, E. A., Nicholls, M. G. et al. (1996) Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am. J. Physiol. 271, R373-R380
104. Misono, K. S. (2002) Natriuretic peptide receptor: structure and signaling. Mol. Cell. Biochem. 230, 49-60
105. Leitman, D. C., Andresen, J. W., Kuno, T. et al. (1986) Identification of multiple binding sites for atrial natriuretic factor by affinity cross-linking in cultured endothelial cells. J. Biol. Chem. 261, 11650-11655
106. Leitman, D. C., Andresen, J. W., Catalano, R. M., Waldman, S. A., Tuan, J. J. and Murad, F. (1988) Atrial natriuretic peptide binding, cross-linking, and stimulation of cyclic GMP accumulation and particulate guanylate cyclase activity in cultured cells. J. Biol. Chem. 263, 3720-3728
107. Leitman, D. C., Waldman, S. A. and Murad, F. (1991) Identification of atrial natriuretic peptide receptors in cultured cells. Methods Enzymol. 195, 436-446
108. Chang, M., Lowe, D. G., Lewis, M., Hellmiss, R., Chen, E. and Goeddel, D. V. (1989) Differential activation by atrial and brain natriuretic peptides of two different receptor guanyl cyclases. Nature (London) 341, 68-72
109. Tremblay, J., Desjardins, R., Hum, D., Gutkowska, J. and Hamet, P. (2002) Biochemistry and physiology of the natriuretic peptide receptor guanyl cyclases. Mol. Cell. Biochem. 230, 31-47
110. Schenk, D. B., Phelps, M. N., Porter, J. G., Scarborough, R. M., McEnroe, G. A. and Lewicki, J. A. (1985) Identification of the receptor for atrial natriuretic factor on cultured vascular cells. J. Biol. Chem 260, 14887-14890
111. Anand-Srivastava, M. B. and Trachte, G. J. (1993) Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol. Rev. 45, 455-497
112. Tseng, Y. C., Lahiri, S., Sellitti, D. F., Burman, K. D., D'Avis, J. C. and Wartofsky, L. (1990) Characterization by affinity cross-linking of a receptor for atrial natriuretic peptide in cultured human thyroid cells associated with reductions in both adenosine 3′,5′-monophosphate production and thyroglobulin secretion. J. Clin. Endocrinol. Metab. 70, 528-533
113. Anand-Srivastava, M. B., Franks, D. J., Cantin, M. and Genest, J. (1984) Atrial natriuretic factor inhibits adenylate cyclase activity. Biochem. Biophys. Res. Commun. 121, 855-862
114. Anand-Srivastava, M. B., Cantin, M. and Genest, J. (1985) Inhibition of pituitary adenylate cyclase by atrial natriuretic factor. Life Sci. 36, 1873-1879
115. Anand-Srivastava, M. B., Vinay, P., Genest, J. and Cantin, M. (1986) Effect of atrial natriuretic factor on adenylate cyclase in various nephron segments. Am. J. Physiol. 251, F417-F423
116. Anand-Srivastava, M. B. and Cantin, M. (1986) Atrial natriuretic factor receptors are negatively coupled to adenylate cyclase in cultured atrial and ventricular cardiocytes. Biochem. Biophys. Res. Commun. 138, 427-436
117. Anand-Srivastava, M. B. (1992) Characterization of ANF-R2 receptor-mediated inhibition of adenylate cyclase. Mol. Cell. Biochem. 113, 83-92
118. Anand-Srivastava, M. B., Palaparti, A. and Pion, J. (1997) Differential regulation of G-protein expression by vasoactive peptides. Mol. Cell. Biochem. 176, 21-27
119. Chinkers, M. and Garbers, D. L. (1989) The protein kinase domain of the ANP receptor is required for signaling. Science (Washington, D.C.) 245, 1392-1394
120. Resink, T. J., Scott-Burden, T., Baur, U., Jones, C. R. and Buhler, F. R. (1988) Atrial natriuretic peptide induces breakdown of phosphatidylinositol phosphates in cultured vascular smooth-muscle cells. Eur. J. Biochem. 172, 499-505
121. Hirata, M., Chang, C. H. and Murad, F. (1989) Stimulatory effects of atrial natriuretic factor on phosphoinositide hydrolysis in cultured bovine aortic smooth muscle cells. Biochim. Biophys. Acta 1010, 346-351
122. Rapoport, R. M. (1986) Cyclic guanosine monophosphate inhibition of contraction may be mediated through inhibition of phosphatidylinositol hydrolysis in rat aorta. Circ. Res. 58, 407-410
123. Barnett, R., Ortiz, P. A., Blaufox, S., Singer, S., Nord, E. P. and Ramsammy, L. (1990) Atrial natriuretic factor alters phospholipid metabolism in mesangial cells. Am. J. Physiol. 258, C37-C45
124. Meyer-Lehnert, H., Caramelo, C., Tsai, P. and Schrier, R. W. (1988) Interaction of atriopeptin III and vasopressin on calcium kinetics and contraction of aortic smooth muscle cells. J. Clin. Invest. 82, 1407-1414
125. Vesely, D. L. and Giordano, A. T. (1992) Atrial natriuretic factor-like peptide and its prohormone within single cell organisms. Peptides 13, 177-182
126. Vesely, D. L., Gower, Jr, W. R. and Giordano, A. T. (1993) Atrial natriuretic peptides are present throughout the plant kingdom and enhance solute flow in plants. Am. J. Physiol. 265, E465-E477
127. Holliday, L. S., Dean, A. D., Greenwald, J. E. and Glucks, S. L. (1995) C-type natriuretic peptide increases bone resorption in 1,25-dihydroxyvitamin D3-stimulated mouse bone marrow cultures. J. Biol. Chem. 270, 18983-18989
128. Suda, M., Tanaka, K., Fukushima, M. et al. (1996) C-type natriuretic peptide as an autocrine/paracrine regulator of osteoblast. Evidence for possible presence of bone natriuretic peptide system. Biochem. Biophys. Res. Commun. 223, 1-6
129. Vollmar, A., Foerster, R. and Schulz, R. (1987) Effects of atrial natriuretic peptide on phagocytosis and respiratory burst in murine macrophages. Eur. J. Pharmacol. 319, 279-285
130. Biselli, R., Farrace, S., De Simone, C. and Fattorossi, A. (1996) Potentiation of human polymorphonuclear leukocyte activation by atrial natriuretic peptide. Inhibitory effect of carnitine congeners. Inflammation 20, 33-42
131. Elferink, J. G. and De Koster, B. M. (1995) Atrial natriuretic factor stimulates migration by human neutrophils. Eur. J. Pharmacol. 288, 335-340
132. Wiedermann, C. J., Niedermuhlbichler, M., Braunsteiner, H. and Widermann, C. J. (1992) Priming of polymorphonuclear neutrophils by atrial natriuretic peptide in vitro. J. Clin. Invest. 89, 1580-1586
133. Opgenorth, T. J., Budzik, G. P., Mollison, K. W., Davidsen, S. K., Holst, M. R. and Holleman, W. H. (1990) Atrial peptides induce mast cell histamine release. Peptides 11, 1003-1007
134. Moss, R. B. and Golightly, M. G. (1991) In vitro enhancement of natural cytotoxicity by atrial natriuretic peptide fragment 4-28. Peptides 12, 851-854
135. Debinski, W., Kuchel, O. and Buu, N. T. (1990) Atrial natriuretic factor is a new neuromodulatory peptide. Neuroscience 36, 15-20
136. Levin, E. R. (1989) Atrial natriuretic factor: neuromodulator of the central nervous system regulation of blood pressure. Am. J. Hypertens. 2, 594-598
137. Diestelhorst, M. and Kriegelstein, G. K. (1989) The intraocular pressure response of human atrial natriuretic factor in glaucoma. Int. Opthalmol. 13, 99-101
138. Wolfensberger, T. J., Singer, D. R., Freegard, T., Markandu, N. D., Buckley, M. G. and MacGregar, G. A. (1994) Evidence for a new role of natriuretic peptide: control of intraocular pressure. Br. J. Opthalmol. 78, 446-448
139. Clarkson, P. B., Wheeldon, N. M., Macleod, C., Coutie, W. and MacDonald, T. M. (1995) Acute effects of atrial natriuretic peptide on left ventricular diastolic function. A pulsed wave Doppler study in man. Eur. Heart J. 16, 1710-1715
140. Meulemans, A. L., Sipido, E. R., Sys, S. V. and Brytsaert, D. L. (1988) Atriopeptin III induces early relaxation of isolated mamalian papillary muscle. Circ. Res. 62, 1171-1174
141. Levin, E. R., Gardner, D. G. and Samson, W. K. (1998) Natriuretic peptides. N. Engl. J. Med. 339, 321-328
142. Needleman, P. and Greenwald, J. E. (1986) Atriopeptin: a cardiac hormone intimately involved in fluid, electrolyte, and blood-pressure homeostasis. N. Engl. J. Med. 314, 828-834
143. Richards, A. M., Nicholls, M. G. and Espiner, E. A. (1995) Natriuretic peptides. Clin. Sci. 88, 18-21
144. Abell, T. J., Richards, A. M., Ikram, H., Espiner, E. A. and Yandle, T. (1989) Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet-derived growth factor. Biochem. Biophys. Res. Commun. 160, 1392-1396
145. Itoh, H., Pratt, R. E. and Dzau, V. J. (1990) Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J. Clin. Invest. 86, 1690-1697
146. Itoh, H., Pratt, R. E., Ohno, M. and Dzau, V. J. (1992) Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells. Hypertension 19, 758-761
147. Hamad, A. M., Johnson, S. R. and Knox, A. J. (1999) Antiproliferative effects of NO and ANP in cultured human airway smooth muscle. Am. J. Physiol. 277, L910-L918
148. Schulte, E. A., Saleh, H. and Schlatter, E. (2000) Diadenosine polyphosphates and atrial natriuretic peptide are antiproliferative in rat mesangial cells. Cell Physiol. Biochem. 10, 57-64
149. Garcia-Ocana, A., Penaranda, C. and Esbrit, P. (1996) Comparison of antiproliferative effects of atrial natriuretic peptide and transforming growth factor β on rabbit kidney proximal tubule cells. Life Sci. 58, 251-258
150. Hutchinson, H. G., Trindade, P. T., Cunanan, D. B., Wu, C. F. and Pratt, R. E. (1997) Mechanisms of natriuretic-peptide-induced growth inhibition of vascular smooth muscle cells. Cardiovasc. Res. 35, 158-167
151. Morishige, K., Shimokawa, H., Yamawaki, T. et al. (2000) Local adenovirus-mediated transfer of C-type natriuretic peptide suppresses vascular remodeling in porcine coronary arteries in vivo. J. Am. Coll. Cardiol. 35, 1040-1047
152. Dzau, V. J. (1993) The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes. Curr. Opin. Nephrol. Hypertens. 2, 27-32
153. Chen, H. H., Schirger, J. A., Chau, W. L. et al. (1999) Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation 100, 2443-2448
154. Fett, D. L., Cavero, P. G. and Burnett, Jr, J. C. (1993) Low-dose atrial natriuretic factor and furosemide in experimental acute congestive heart failure. J. Am. Soc. Nephrol. 4, 162-167
155. Fukai, D., Wada, A., Tsutamoto, T. and Kinoshita, M. (1998) Short-term and long-term inhibition of endogenous atrial natriuretic peptide in dogs with early-stage heart failure. Jpn. Circ. J. 62, 604-610
156. Grantham, J. A. and Burnett, J. C. (1997) Natriuretic peptides in cardiovascular disease: a focus on congestive heart failure. In Natriuretic Peptides in Health and Disease (Samson, W. K. and Levin, E. R., eds.), pp. 309-326, Humana Press, Totowa, NJ
157. 126). Biochem. Biophys. Res. Commun. 135, 987-993
158. van der Zander, K., Houben, A. J., Kroon, A. A., De Mey, J. G., Smits, P. A. and de Leeuw, P. W. (2002) Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man. J. Hypertens. 20, 493-499
159. Doorenbos, C. J., Blauw, G. J. and van Brummelen, P. (1991) Arterial and venous effects of atrial natriuretic peptide in the human forearm. Am. J. Hypertens. 4, 333-340
160. Breuhaus, B. A., Saneii, H. H., Brandt, M. A. and Chimoskey, J. E. (1985) Atriopeptin II lowers cardiac output in conscious sheep. Am. J. Physiol. 249, R776-R780
161. Lappe, R. W., Smits, J. F., Todt, J. A., Debets, J. J. and Wendt, R. L. (1985) Failure of atriopeptin II to cause arterial vasodilation in the conscious rat. Circ. Res. 56, 606-612
162. Groban, L., Ebert, T. J., Kreis, D. U., Skelton, M. M., Van Wynsberghe, D. M. and Cowley, A. W. (1989) Hemodynamic, renal, and hormonal responses to incremental ANF infusions in humans. Am. J. Physiol. 256, F780-F786
163. Espiner, E. A. (1997) Physiology of natriuretic peptides: cardiovascular function. In Natriuretic Peptides in Health and Disease (Samson, W. K. and Levin, E. R., eds.), pp. 123-146, Humana Press, Totowa, NJ
164. Groban, L., Cowley, A. W. and Ebert, T. J. (1990) Atrial natriuretic peptide augments forearm capillary filtration in humans. Am. J. Physiol. 259, H258-H263
165. Munzel, T., Drexler, H., Holtz, J., Kurtz, S. and Just, H. (1991) Mechanisms involved in the response to prolonged infusion of atrial natriuretic factor in patients with chronic heart failure. Circulation 83, 191-201
166. Ljutic, D. and Rumboldt, Z. (1989) The influence of the atrial natriuretic factor on venous tone in man. Int. J. Clin. Pharmacol. Res. 9, 255-260
167. Zhang, L. M., Castresana, M. R., McDonald, M. H., Johnson, J. H. and Newman, W. H. (1996) Response of human artery, vein, and cultured smooth muscle cells to atrial and C-type natriuretic peptides. Crit. Care Med. 24, 306-310
168. Hughes, A. D., Nielsen, H., Thom, S., Martin, G. N. and Sever, P. S. (1987) The effect of atrial natriuretic peptide on human blood vessels. J. Hypertens. 5, 51-53
169. Olson, K. R., Conklin, D. J., Farrell, A. P. et al. (1997) Effects of natriuretic peptides and nitroprusside on venous function in trout. Am. J. Physiol. 273, R527-R539
170. Schmitt, M., Nightingale, A. K., Broadley, A. et al. (2001) Atrial natriuretic peptide regulates venous capacitance in man. Circulation 104 (suppl. 2), II-393
171. Schulz, S. (1999) Targeted gene disruption in the development of mouse models to elucidate the role of receptor guanyl cyclase signaling pathways in physiological function. Methods 19, 551-558
172. Melo, L., Steinhelper, M., Pang, S., Tse, Y. and Ackermann, U. (2000) ANP in regulation of arterial pressure and fluid-electrolyte balance: lessons from genetic mouse models. Physiol. Genomics 3, 45-58
173. Rubattu, S., Lee-Kirsch, M. A., DePaolis, P. et al. (1999) Altered structure, regulation, and function of the gene encoding the atrial natriuretic peptide in the stroke-prone spontaneously hypertensive rat. Circ. Res. 85, 900-905
174. Rubattu, S., Ridker, P., Stampfer, M., Volpe, M., Hennekens, C. and Lindpaintner, K. (1999) The gene encoding atrial natriuretic peptide and the risk of human stroke. Circulation 100, 1722-1726
175. Rubattu, S. and Volpe, M. (2001) The atrial natriuretic peptide: a changing view. J. Hypertens. 19, 1923-1931
176. Takahashi, N. and Smithies, O. (1999) Gene targeting approaches to analysing hypertension. J. Am. Soc. Nephrol. 10, 1598-1605
177. Kitashiro, S., Sugiura, T., Takayama, Y. et al. (1999) Long-term administration of atrial natriuretic peptide in patients with acute heart failure. J. Cardiovasc. Pharmacol. 33, 948-952
178. Munzel, T., Kurz, S., Holtz, J. et al. (1992) Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation 86, 1089-1098
179. Kikuchi, M., Nakamura, M., Suzuki, T., Sato, M., Takino, T. and Hiramori, K. (2001) Usefulness of carperitide for the treatment of refractory heart failure due to severe acute myocardial infarction. Jpn. Heart J. 42, 271-280
180. Ando, S., Imaizumi, T., Harada, S., Hirooka, Y. and Takeshita, A. (1992) Atrial natriuretic peptide increases human capillary filtration and venous distensibility. J. Hypertens. 10, 451-457
181. Cuneo, R. C., Espiner, E. A., Nicholls, M. G., Yandle, T. G., Joyce, S. L. and Gilchrist, N. L. (1986) Renal, hemodynamic, and hormonal responses to atrial natriuretic peptide infusions in normal man, and effect of sodium intake. J. Clin. Endocrinol. Metab. 63, 946-953
182. Weidmann, P., Hellmueller, B., Uehlinger, D. E. et al. (1986) Plasma levels and cardiovascular, endocrine, and excretory effects of atrial natriuretic peptide during different sodium intakes in man. J. Clin. Endocrinol. Metab. 62, 1027-1036
183. Floras, J. S. (1990) Sympathoinhibitory effects of atrial natriuretic factor in normal humans. Circulation 81, 1860-1873
184. Floras, J. S. (1995) Inhibitory effect of atrial natriuretic factor on sympathetic ganglionic neurotransmission in humans. Am. J. Physiol. 269, R406-R412
185. Richards, A. M., Nicholls, M. G., Ikram, H., Webster, M. W., Yandle, T. G. and Espiner, E. A. (1985) Renal, haemodynamic, and hormonal effects of human α atrial natriuretic peptide in healthy volunteers. Lancet 1, 545-549
186. Crozier, I. G., Nicholls, M. G., Ikram, H., Espiner, E. A., Gomez, H. J. and Warner, N. J. (1986) Haemodynamic effects of atrial peptide infusion in heart failure. Lancet 2, 1242-1245
187. Crozier, I. G., Richards, A. M., Nicholls, M. G., Espiner, E. A. and Ikram, H. (1989) Inefficacy of daily single bolus dose atrial natriuretic factor in chronic congestive heart failure. Am. J. Cardiol. 64, 948-950
188. Wambach, G., Schittenhelm, U., Bonner, G. and Kaufmann, W. (1989) Renal and adrenal resistance against atrial natriuretic peptide in congestive heart failure: effect of angiotensin I-converting-enzyme inhibition. Cardiology 76, 418-427
189. Cody, R. J., Atlas, S. A., Laragh, J. H. et al. (1986) Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J. Clin. Invest 78, 1362-1374
190. Raya, T. E., Lee, R. W., Westhoff, T. and Goldman, S. (1989) Captopril restores hemodynamic responsiveness to atrial natriuretic peptide in rats with heart failure. Circulation 80, 1886-1892
191. Kalra, P. R. and Coats, A. J. (2002) Therapeutic potential of the natriuretic peptide system. Br. J. Cardiol. 9, 273-279
192. Wambach, G., Schittenhelm, U., Stimpel, M., Bonner, G. and Kaufmann, W. (1989) Natriuretic action of ANP is blunted by ACE inhibition in humans. J. Cardiovasc. Pharmacol. 13, 748-753
193. Kotridis, P., Kokkas, B., Karamouzis, M. et al. (2002) Plasma atrial natriuretic peptide in essential hypertension after treatment with irbersartan. Blood Pressure 11, 91-94
194. Atherton, J. J., Moore, T. D., Lele, S. S. et al. (1997) Diastolic ventricular interaction in chronic heart failure. Lancet 349, 1720-1724
195. Serizawa, T., Hirata, Y., Kobmoto, O. et al. (1988) Acute hemodynamic effects of alpha human atrial natriuretic polypeptide in patients with congestive heart failure. Jpn. Heart J. 29, 143-149
196. Drummer, C., Kentsch, M., Otter, W., Heer, M., Herten, M. and Gerzer, R. (1997) Increased renal natriuretic peptide (urodilatin) excretion in heart failure patients. Eur. J. Med. Res. 2, 347-354
197. Saxenhofer, H., Raselli, A., Weidmann, P. et al. (1990) Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am. J. Physiol. 259, F832-F838
198. Riegger, G. A., Eisner, D., Forssmann, W. G. and Kromer, E. P. (1990) Effects of ANP (95-126) in dogs before and after induction of heart failure. Am. J. Physiol. 259, H1643-H1648
199. Kentsch, M., Ludwig, D., Drummer, C., Gerzer, R. and Muller-Escb, G. (1992) Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure. Eur. J. Clin. Invest. 22, 662-669
200. Elsner, D., Muders, F., Muntze, A., Kromer, E. P., Forssmann, W. G. and Riegger, G. A. (1995) Efficacy of prolonged infusion of urodilatin [ANP(95-126)] in patients with congestive heart failure. Am. Heart J. 129, 766-773
201. Forssmann, W., Meyer, M. and Forssmann, K. (2001) The renal urodilatin system: clinical implications. Cardiovasc. Res. 51, 450-462
202. Colucci, W. S. (2001) Nesiritide for the treatment of decompensated heart failure. J. Card. Failure 7, 92-100
203. Mills, R. M. and Hobbs, R. E. (2002) How to use nesiritide in treating decompensated heart failure. Cleveland Clin. J. Med. 69, 252-256
204. Silver, M. A., Horton, D. P., Ghali, J. K. and Elkayam, U. (2002) Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J. Am. Coll. Cardiol. 19, 798-803
205. Young, J. B. for the VMAC Investigators (2002) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA, J. Am. Med. Assoc. 287, 1531-1540
206. Mills, R. M., LeJemtel, T. H., Horton, D. P. et al. (1999) Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J. Am. Coll. Cardiol. 34, 155-162
207. Colucci, W. S., Elkayam, U., Horton, D. P. et al. (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N. Engl. J. Med. 343, 246-253
208. Burger, A. J., Elkayam, U., Neibaur, M. T. et al. (2001) Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am. J. Cardiol. 88, 35-39
209. Burger, A. J., Horton, D. P., LeJemtel, T. et al. (2002) Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart J. 144, 1102-1108
210. Marcus, L. S., Hart, D., Packer, M. et al. (1996) Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 94, 3184-3189
211. Yoshimura, M., Yasue, H., Morita, E. et al. (1991) Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84, 1581-1588
212. Abraham, W. T., Lowes, B. D., Ferguson, D. A. et al. (1998) Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J. Card. Failure 4, 37-44
213. Corti, R., Burnett, Jr, J. C., Rouleau, J. L., Ruschitzka, F. and Luscher, T. F. (2001) Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 104, 1856-1862
214. Sagnella, G. A. (2002) Vasopeptidase inhibitors. J. Renin Angiotensin Aldosterone Syst. 3, 90-95
215. Dawson, A. and Struthers, A. D. (2002) Vasopeptidase inhibitors in heart failure. J. Renin Angiotensin Aldosterone Syst. 3, 156-159
216. Ferro, C. J., Spratt, J. C., Haynes, W. G. and Webb, D. J. (1998) Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 97, 2323-2330
217. Trippodo, N. C., Fox, M., Natarajan, V., Panchal, B. C., Dorso, C. R. and Asaad, M. M. (1993) Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme in cardiomyopathic hamsters with compensated heart failure. J. Pharmacol. Exp. Ther. 267, 108-116
218. Trippodo, N. C., Gabel, R. A., Harvey, C. M., Asaad, M. M. and Rogers, W. L. (1991) Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats. J. Cardiovasc. Pharmacol. 18, 308-316
219. Trippodo, N. C., Robl, J. A., Asaad, M. M. et al. (1995) Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J. Pharmacol. Exp. Ther. 275, 745-752
220. Trippodo, N. C., Fox, M., Monticello, T. M., Panchal, B. C. and Asaad, M. M. (1999) Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J. Cardiovasc. Pharmacol. 34, 782-790
221. Chen, H. H., Lainchbury, J. G., Matsuda, Y., Harty, G. J. and Burnett, Jr, J. C. (2001) Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Hypertension 38, 187-191
222. Cataliotti, A., Boerrigter, G., Chen, H. H. et al. (2002) Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation 105, 639-644
223. Chen, H. H., Cataliotti, A. and Burnett, Jr, J. C. (2001) Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure. Curr. Hypertens. Rep. 3, S15-S21
224. French, J. F., Flynn, G. A., Giroux, E. L. et al. (1994) Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J. Pharmacol. Exp. Ther. 268, 180-186
225. Raut, R., Rouleau, J. L., Blais, Jr, C. et al. (1999) Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. Am. J. Physiol. 276, H1769-H1779
226. Sagnella, G. A. (2000) Practical implications of current natriuretic peptide research. J. Renin Angiotensin Aldosterone Syst. 1, 304-315
227. Messerli, F. H. and Nussberger, J. (2000) Vasopeptidase inhibition and angio-oedema. Lancet 356, 608-609
228. McClean, D. R., Ikram, H., Garlick, A. H., Richards, A. M., Nicholls, M. G. and Crozier, I. G. (2000) The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J. Am. Coll. Cardiol. 36, 479-486
229. Rouleau, J. L., Pfeffer, M. A., Stewart, D. J. et al. (2000) Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 356, 615-620
230. McClean, D. R., Ikram, H., Mehta, S. et al. (2002) Vasopeptidase inhibition with Omapatrilat in chronic heart failure: Acute and long-term hemodynamic and neurohormonal effects. J. Am. Coll. Cardiol. 19, 2034-2041
231. Coats, A. J. (2002) Omapatrilat - the story of Overture and Octave. Int. J. Cardiol. 86, 1-4
232. Packer, M., Califf, R. M., Konstam, M. A. et al. (2002) Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106, 920-926
233. Seymour, A. A., Asaad, M. M., Abboa-Offei, B. E., Rovnyak, P. L., Fennell, S. and Rogers, W. L. (1992) Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats. J. Pharmacol. Exp. Ther. 262, 60-70
234. Seymour, A. A., Abboa-Offei, B. E., Smith, P. L., Mathers, P. D., Asaad, M. M. and Rogers, W. L. (1995) Potentiation of natriuretic peptides by neutral endopeptidase inhibitors. Clin. Exp. Pharmacol. Physiol. 22, 63-69
235. Rademaker, M. T., Charles, C. J., Cooper, G. J. et al. (2002) Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure. Hypertension 19, 93-98
236. Chen, H. H., Grantham, J. A., Schirger, J. A., Jougasaki, M., Redfield, M. M. and Burnett, Jr, J. C. (2000) Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J. Am. Coll. Cardiol. 36, 1706-1712
237. Chen, H. H., Lainchbury, J. G., Harty, G. J. and Burnett, Jr, J. C. (2002) Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation 105, 999-1003
238. Hirooka, Y., Takeshita, A., Imaizumi, T. et al. (1990) Attenuated forearm vasodilative response to intra-arterial atrial natriuretic peptide in patients with heart failure. Circulation 82, 147-153
239. Ikenouchi, H., Sato, H., Hirata, Y., Iizuka, M., Serizawa, T. and Sugimoto, T. (1989) Lack of venodilative activity of α human atrial natriuretic polypeptide in patients with congestive heart failure. Jpn. Heart J. 30, 443-457
240. Tsunoda, K., Mendelsohn, F. A., Sexton, P. M., Chai, S. Y., Hodsman, G. P. and Johnston, C. I. (1988) Decreased atrial natriuretic peptide binding in renal medulla in rats with chronic heart failure. Circ. Res. 62, 155-161
241. Tsutamoto, T., Kanamori, T., Morigami, N., Sugimoto, Y., Yamaoka, O. and Kinoshita, M. (1993) Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation 87, 70-75
242. Wei, C. M., Kao, P. C., Lin, J. T., Heublein, D. M., Schaff, H. V. and Burnett, Jr, J. C. (1993) Circulating β-atrial natriuretic factor in congestive heart failure in humans. Circulation 88, 1016-1020
243. Matsukawa, N., Grzesik, W. J., Takahashi, N. et al. (1999) The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc. Natl. Acad. Sci. U.S.A. 96, 7403-7408
244. Naruko, T., Ueda, M., and Haze, K. (1997) Natriuretic peptide receptor expression in human failing hearts. Circulation 96 (suppl. I), A1476
245. Andreassi, M. G., Del Ry, S., Palmieri, C., Clerico, A., Biagini, A. and Giannessi, D. (2001) Up-regulation of 'clearance' receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Eur. J. Heart Failure 3, 407-414
246. Schiffrin, E. L. (1988) Decreased density of binding sites for atrial natriuretic peptide on platelets of patients with severe congestive heart failure. Clin. Sci. 74, 213-218
247. Suzuki, N., Shimomura, H., Radany, E. W. et al. (1984) A peptide associated with eggs causes a mobility shift in a major plasma membrane protein of spermatozoa. J. Biol. Chem. 259, 14874-14879
248. Ward, G. E., Garbers, D. L. and Vacquier, V. D. (1985) Effects of extracellular egg factors on sperm guanylate cyclase. Science (Washington, D.C.) 227, 768-770
249. Potter, L. R. and Garbers, D. L. (1992) Dephosphorylation of the guanylyl cyclase-A receptor causes desensitization. J. Biol. Chem. 267, 14531-14534.
250. Potter, L. R. and Garbers, D. L. (1994) Protein kinase C-dependent desensitization of the atrial natriuretic peptide receptor is mediated by dephosphorylation. J. Biol. Chem. 269, 14636-14642
251. Hussain, M. B., MacAllister, R. J., and Hobbs, A. J. (2001) Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases. Am. J. Physiol. 280, H1151-H1159
252. Wennberg, P. W., Miller, V. M., Rabelink, T. and Burnett, Jr, J. C. (1999) Further attenuation of endothelium-dependent relaxation imparted by natriuretic peptide receptor antagonism. Am. J. Physiol. 277, H1618-H1621
253. Nightingale, A. K., Blackman, D. J., Ellis, G. R. et al. (2001) Preservation of venous endothelial function in the forearm venous capacitance bed of patients with chronic heart failure despite arterial endothelial dysfunction. J. Am. Coll. Cardiol. 37, 1062-1068
254. Knecht, M., Pagel, I., Langenickel, T. et al. (2002) Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci. 71, 2701-2712
255. von Geldern, T. W., Budzik, G. P., Dillon, T. P. et al. (1990) Atrial natriuretic peptide antagonists: biological evaluation and structural correlations. Mol. Pharmacol. 38, 771-778
256. von Geldern, T. W., Rockway, T. W., Davidsen, S. K. et al. (1992) Small atrial natriuretic peptide analogues: design, synthesis, and structural requirements for guanylate cyclase activation. J. Med. Chem. 35, 808-816
257. Elsner, D., Kromer, E. P. and Riegger, G. A. (1989) Hemodynamic, renal, and hormonal effects of 8-Br-cyclic GMP in conscious dogs with and without congestive heart failure. J. Cardiovasc. Pharmacol. 14, 241-247
258. Struthers, A. D. (1996) Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J. Card. Failure 2, 47-54
259. Farquharson, C. A. and Struthers, A. D. (2002) Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J. Am. Coll. Cardiol. 39, 767-775
260. Granger, J. P., Burnett, Jr, J. C., Romero, J. C., Opgenorth, T. J., Salazar, J. and Joyce, M. (1987) Elevated levels of atrial natriuretic peptide during aldosterone escape. Am. J. Physiol. 252, R878-R882
261. Tesar, V., Spicak, J., Horky, K. et al. (1994) Renal resistance to atrial natriuretic factor as a cause of the escape failure phenomenon in patients with non-ascitic liver cirrhosis. Cas. Lek. Cesk. 133, 111-115